Price: $77.01 | Market cap: ~$9.1B | 52-wk range: $52.72–$82.22 | Sector: Healthcare / Biotechnology Data as of: FY2025 10-K (filed 2026-02-17) + Q1 FY2026 (filed 2026-05-11)
1. What It Is
Halozyme is a commercial-stage biopharmaceutical company built around a single proprietary platform: ENHANZE, a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily breaks down hyaluronan under the skin, allowing large-volume biologic drugs (typically administered by IV infusion) to instead be injected subcutaneously in minutes. Halozyme does not sell these drugs itself — it licenses ENHANZE to large pharma partners (Roche/Genentech, Janssen/J&J, Pfizer, argenx, Bristol Myers Squibb, Eli Lilly, AbbVie, Alexion, ViiV, among others), who build it into their own subcutaneous drug formulations (e.g., Darzalex Faspro, Phesgo, Tecentriq SC, Rituxan Hycela/MabThera SC, HYQVIA). Halozyme collects upfront/milestone payments plus running royalties on partner net sales — a licensing/royalty model, not a traditional biotech R&D-and-commercialize model.
2. The "Exponential" Thesis — With a Caveat
The forward growth drivers are real: (1) a growing roster of ENHANZE-enabled drugs moving through partner pipelines and into commercial launch (each new SC conversion or newly approved combination adds a royalty stream), (2) contractual royalty step-ups as partner drugs cross sales thresholds, (3) continued conversion of blockbuster IV oncology/immunology franchises to SC formats (a structural trend across pharma favoring at-home/faster-infusion administration), and (4) new partnership signings that add optionality without R&D capital outlay from Halozyme.
That said, the quant profile here (+27% fwd revenue growth, +15% acceleration) is meaningfully more modest than the hypergrowth names this screen is built around (LITE, CRDO, ASND-type profiles). This is honestly a moat/cash-flow compounder story, not a hypergrowth story — the label "Genomics/biotech exponential" is a loose fit here. Halozyme's growth is driven by royalty-stream accumulation and step-ups on an existing, diversified partner base, not by pipeline binary events or new-market creation. It's a high-quality compounder wearing a growth-screen label. Worth stating plainly per the task's flag criteria: this ticker does not fit the same mold as the platform/hypergrowth names elsewhere in this batch.
3. Financial Health — Real Numbers
Halozyme is a rare biotech: genuinely profitable and free-cash-flow generative, and has been consistently so since roughly FY2020-21.
Revenue trend (annual): | FY | Revenue | YoY | Gross Margin | Net Margin | |---|---|---|---|---| | 2021 | $443M | — | 81.6% | 90.8%* | | 2022 | $660M | +48% | 78.9% | 30.6% | | 2023 | $829M | +26% | 76.8% | 34.0% | | 2024 | $1,015M | +22% | 84.3% | 43.7% | | 2025 | $1,397M | +38% | 78.1% | 22.7% |
*2021 net margin inflated by a large one-time tax benefit (income tax expense of –$154M, i.e., a tax benefit), not operating strength — a good early example of the noise later discussed in the PEG section.
Gross margins have run 76–84% for five straight years — consistent with a royalty/licensing model where cost of revenue is mostly partner manufacturing/supply cost, not R&D-heavy COGS. GAAP operating margins have been positive every year since 2020 (except transient swings from litigation/legal settlement charges), confirming this is a real, profitable operating business, not an adjusted-EBITDA story.
Balance sheet (FY2025): Total assets $2.53B; cash + short-term investments only $143M (down sharply from $596M in FY2024) after a $726M acquisition (Elektrofi, closed 2025) funded partly with $451M of new long-term debt issuance. Total debt is now $2.14B, largely 0.25%–1.0% convertible senior notes (2027/2029 tranches per historical filings) — up materially from $1.51B in FY2024. Net debt/EBITDA is roughly 3.5x on FY2025 EBITDA (~$573M), which is a step up in leverage versus prior years (~2.1x in FY2024) and worth watching, though covered comfortably given the cash-generative model (interest coverage ~45x). Stockholders' equity is thin (~$49M) because of years of historical share buybacks against a deficit-heavy capital structure — normal for this kind of royalty compounder but means tangible book value is negative (~-$12.6/share) — irrelevant to the thesis but flag it so it isn't misread as a balance-sheet red flag on its own.
Free cash flow: FCF has been robust and growing — $236M (2022), $373M (2023), $468M (2024), $645M (2025). FCF conversion from operating cash flow is consistently >95%, reflecting very low capex needs (a licensing business doesn't need factories).
Capital return: Halozyme has been an active repurchaser of its own stock — $200M (2022), $402M (2023), $250M (2024), $342M (2025) in buybacks — funded from operating cash flow, not equity issuance. No dividend. Share count has fallen from ~137M (2022) to ~118M (2025), a genuine and sustained capital-return program, distinct from most biotechs which dilute continuously.
4. Competitive Position / Moat
ENHANZE's moat rests on (a) patented rHuPH20 enzyme IP and manufacturing know-how, (b) deep integration into partners' regulatory filings (once a drug is approved with ENHANZE built in, switching costs for the partner are very high — re-filing with a different delivery technology means new trials), and (c) a first-mover, decade-plus head start with limited direct competitors offering a comparably validated recombinant hyaluronidase at commercial scale. This is a real, structural moat — not merely branding.
Risks to the moat: rHuPH20's core composition-of-matter patents have substantially expired or are expiring through the back half of this decade (Halozyme has historically disclosed method-of-use and formulation patents extending protection into the early-to-mid 2030s for specific products, but the earliest core IP is aging). Competing hyaluronidase/subcutaneous-delivery approaches exist (e.g., other PH20 formulations, on-body injector/device-based SC delivery as an alternative route that bypasses hyaluronidase entirely) — the FMP data doesn't give patent-expiry detail, so this needs verification against the 10-K IP section directly, but it's a genuine multi-year overhang worth investor diligence.
Partner concentration: Roche/Genentech and Janssen/J&J have historically represented a large share of ENHANZE royalty revenue (Darzalex Faspro alone is a significant single-product exposure). The FMP data doesn't break out revenue by partner, but this concentration is a known, real risk — a single large partner's drug facing biosimilar/generic competition or formulary setbacks would be a material single-name risk to consolidated royalty revenue.
5. Valuation — Multiples vs. Growth, and the PEG Mechanism Explained
Current multiples (FY2025 basis): P/E ~25.5x (trailing GAAP), EV/EBITDA ~17.6x, EV/Sales ~7.2x, P/FCF ~12.5x, FCF yield ~8%.
On the PEG of –1.13 (flagged in the brief): the mechanism is clear once you separate revenue growth from EPS growth. Revenue grew a strong +38% in FY2025 ($1.015B → $1.397B). But GAAP EPS fell in FY2025: diluted EPS was $2.56 vs. $3.43 in FY2024 — a decline of roughly 25%, despite the revenue acceleration. The driver is visible directly in the FMP income statement: FY2025 includes a large "non-operating income" swing (+$331M nonoperating item, likely related to the Elektrofi acquisition — could be a contingent-consideration remeasurement, a bargain-purchase gain, or similar one-time item) that inflated operating income optically but was offset by an even larger –$349M "other income/expense" charge below the line, plus a step-up in interest expense from the new convertible debt raised to fund the deal. Net-net, FY2025 GAAP net income of $317M was down from $444M in FY2024 even as revenue grew nearly 40%. A PEG ratio built on trailing GAAP EPS growth (negative) divided by a positive P/E will mechanically produce a negative PEG — this is a data/accounting-lumpiness artifact from acquisition-related one-time items and financing costs, not evidence of a deteriorating business. The underlying operating story (revenue, gross margin, FCF) is healthy; the PEG print should be disregarded or recalculated on a normalized/analyst-forward EPS basis instead.
Consensus forward estimates support the "decelerating-but-still-growing, GAAP-EPS-recovering" read: FY2026E revenue ~$1.77B (+27% — matching the quant profile's growth number), EPS avg $8.11 (a sharp step-up from FY2025's $2.56, reflecting normalization of the one-time items above and a smaller diluted share count from buybacks), growing to FY2027E EPS ~$9.93 and FY2028E ~$11.17. On FY2026E EPS of $8.11, the stock at $77 trades at roughly 9.5x forward P/E — cheap in absolute terms and cheap relative to the ~19–27% forward growth being modeled, if the analyst EPS bridge is trusted. This forward-P/E-vs-growth combination (not the trailing PEG) is the more honest valuation lens here.
Fair-value stance: On EV/EBITDA, HALO at ~17.6x trailing (FY2025) EBITDA is roughly in line with high-quality specialty pharma royalty/licensing peers, not obviously cheap or expensive; on forward P/E (~9.5x FY2026E) it screens cheap if the earnings normalization materializes as modeled. The gap between trailing-GAAP-optically-messy and forward-analyst-clean numbers is the central valuation question for this name — an investor needs to underwrite the FY2026 EPS estimate, not extrapolate FY2025's reported (noisy) EPS.
6. What the Panel Says — IMPORTANT DATA FLAG
The knowledge base contains no genuine coverage of Halozyme Therapeutics. Grep searches for "HALO" (case-insensitive), "Halozyme", and "ENHANZE" across knowledge_base.jsonl returned: - Zero matches for "Halozyme" or "ENHANZE". - 25 matches for "HALO", all of which are false positives. Nearly all are from a single podcast source (compound_and_friends, 2026-05-03 and 2026-03-24 episodes) discussing an entirely unrelated macro/investing framework the speakers call "Halo" — meaning heavy-asset, low-obsolescence businesses resistant to AI disruption (examples cited: Caterpillar, Corning, Prologis, Delta, McDonald's, Walmart, Disney — explicitly not Halozyme). One additional match is a we_study_billionaires reference to the unrelated psychological "halo effect" in behavioral finance.
This directly contradicts the brief's expectation of "conviction +12.1 from n=49 signals" implying rich, substantive panel coverage of Halozyme specifically. The n=49 signal count likely reflects the quant/systematic scoring pipeline (technical, estimate-revision, or factor-based signals), not n=49 genuine qualitative panel mentions of this company — because there are, in fact, zero genuine qualitative mentions in this knowledge base. Any conviction score attributed to "the panel" for HALO should be treated as unsupported by qualitative evidence until a source with actual Halozyme-specific commentary is located. This is a textbook case of a ticker/keyword collision (HALO the ticker vs. "Halo" the unrelated framework name) contaminating a KB search, and it should be corrected in the underlying pipeline (e.g., require co-occurrence with "Halozyme," "ENHANZE," "rHuPH20," or the CIK/ticker in a financial context) rather than a bare "HALO" string match.
7. Key Risks
- rHuPH20 patent/IP durability. Core composition-of-matter patents on the ENHANZE enzyme have substantially aged; formulation and method-of-use patents provide extended protection for specific drug combinations, but the tail risk of biosimilar hyaluronidase or alternative SC-delivery technologies (device-based, on-body injectors) narrowing Halozyme's exclusivity window over the back half of this decade is real and not fully quantifiable from the financial data alone.
- Partner/customer concentration. A small number of large pharma partners (Roche/Genentech, J&J/Janssen in particular, via products like Darzalex Faspro and Phesgo) likely represent an outsized share of royalty revenue. Loss of exclusivity, biosimilar competition, or a formulary setback on any single anchor product would disproportionately hit consolidated results.
- Milestone/one-time-item lumpiness distorting reported growth. As shown directly in the FY2025 financials (large non-operating swings tied to the Elektrofi acquisition, new convertible debt, and a >20-point swing in reported net margin year-over-year despite steady underlying royalty growth), GAAP quarterly and annual comps are noisy. Headline "growth" and "PEG" figures calculated on trailing GAAP EPS can be materially misleading in either direction; underwriting requires normalizing for M&A and financing one-offs.
8. Verdict
Rating: Buy (Satellite/income-compounder role, not a core hypergrowth holding)
Thesis: Halozyme is a genuinely profitable, high-margin (76–84% gross margin), free-cash-flow-generative royalty compounder on a durable but not-invincible drug-delivery IP moat, growing revenue at a respectable (not exponential) ~27% forward clip with real capital returned to shareholders via buybacks — priced attractively on forward earnings (~9.5x FY2026E EPS) if the post-acquisition earnings normalization plays out, though leverage has stepped up materially (net debt/EBITDA ~3.5x) following the debt-funded Elektrofi acquisition.
Valuation stance: Reasonable to cheap on forward P/E and roughly fair on EV/EBITDA; the reported PEG of –1.13 is a GAAP-EPS accounting artifact (acquisition/financing noise), not a genuine growth-vs-multiple red flag, and should not be used to value this name.
Biggest risk: Long-dated rHuPH20 IP/patent-cliff exposure combined with concentrated partner royalty streams (Roche/J&J) — a multi-year, hard-to-quantify overhang rather than a near-term catalyst risk.
Data-quality flag: The knowledge base contains zero substantive analyst/panel commentary on Halozyme — all 25 "HALO" keyword hits are false-positive collisions with an unrelated "Halo" (heavy-asset/AI-resistant) macro framework discussed by a podcast panel. The stated "n=49 signals, conviction +12.1" cannot be corroborated qualitatively from this KB and should be treated as a quant-only signal pending a corrected KB search. Separately, this ticker's growth/acceleration profile (+27%/+15%) is meaningfully lower than the platform/hypergrowth names this screen otherwise targets — HALO is better understood as a profitable royalty/moat compounder than an "exponential growth" biotech, and the screen's framing should be adjusted accordingly for this name.
Sources: FMP cached JSON (profile, quote, income_annual, income_quarter, balance_annual, cashflow_annual, ratios_annual, key_metrics_annual, estimates_annual) as of D:\financial_data_FMP\; knowledge_base.jsonl grep search for "HALO"/"Halozyme"/"ENHANZE". No external web/API calls made.